Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Ophthalmology, Armed Forces Capital Hospital, Seongnam, Korea ; and.
Retina. 2024 Sep 1;44(9):1486-1494. doi: 10.1097/IAE.0000000000004154.
To investigate the significance of intravitreal anti-vascular endothelial growth factor treatment in patients with neovascular age-related macular degeneration and poor visual acuity.
Retrospective study of patients with neovascular age-related macular degeneration with baseline best-corrected visual acuity of ≤20/200. Patients were divided into regular treatment and scarce treatment groups according to whether they underwent consecutive intravitreal anti-vascular endothelial growth factor treatments at intervals of ≤4 months or not.
A total of 131 eyes were included: 87 and 44 eyes in the regular treatment and scarce treatment groups, respectively. The regular treatment group showed significantly improved preservation of lesion size at both Years 1 and 2, with significantly fewer incidences of new subretinal hemorrhage. Improvements in visual acuity, reduction in central subfield macular thickness, and maximal height of choroidal neovascularization were significantly favorable in the regular treatment group at Year 1, and central subfield macular thickness was significantly decreased at Year 2. Survival analysis revealed that the regular treatment group had significantly greater preservation of visual acuity and lesion size than that in the scarce treatment group.
Maintaining intravitreal anti-vascular endothelial growth factor treatment for patients with neovascular age-related macular degeneration and poor vision showed significant advantages in visual acuity and lesion size stability and reduced the incidence of new subretinal hemorrhage, which suggests preservation of paracentral vision.
探讨玻璃体内抗血管内皮生长因子治疗对新生血管性年龄相关性黄斑变性且视力较差患者的意义。
回顾性研究基线最佳矫正视力≤20/200 的新生血管性年龄相关性黄斑变性患者。根据是否在≤4 个月的间隔内连续进行玻璃体内抗血管内皮生长因子治疗，将患者分为常规治疗组和稀少治疗组。
共纳入 131 只眼：常规治疗组 87 只眼，稀少治疗组 44 只眼。常规治疗组在第 1 年和第 2 年均显示出病变大小保存显著改善，且新发视网膜下出血的发生率显著降低。常规治疗组在第 1 年的视力、中心凹下黄斑区厚度减少和脉络膜新生血管最大高度方面均显著改善，且第 2 年中心凹下黄斑区厚度显著减少。生存分析显示，常规治疗组的视力和病变大小保存明显优于稀少治疗组。
对视力较差的新生血管性年龄相关性黄斑变性患者进行玻璃体内抗血管内皮生长因子治疗，可显著提高视力和稳定病变大小，降低新发视网膜下出血的发生率，提示可保存旁中心视力。
